세계의 신장암 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Kidney Cancer Drugs Market is presumed to reach the market size of nearly USD 11.61 Billion by 2032 from USD 6.72 Billion in 2023 with a CAGR of 6.26% under the study period 2024-2032.

Kidney cancer drugs refer to pharmaceutical agents used in the treatment of kidney cancer, also known as renal cell carcinoma (RCC). These drugs include targeted therapies, immunotherapies, and chemotherapy agents designed to inhibit the growth and spread of cancer cells in the kidneys. Targeted therapies typically block specific molecules involved in cancer cell proliferation and angiogenesis, while immunotherapies enhance the immune system's ability to recognize & destroy cancer cells. Chemotherapy drugs may also be used in certain cases to kill rapidly dividing cancer cells. The choice of treatment depends on factors such as cancer stage, genetic mutations present in the tumor, and the patient's overall health.

MARKET DYNAMICS

The rising incidence of kidney cancer globally, coupled with increasing awareness and early detection efforts, is driving demand for effective kidney cancer drugs. Kidney cancer is among the top ten most common cancers worldwide, necessitating continued innovation in treatment approaches to improve patient outcomes. Advancements in molecular biology and genetic profiling have led to the development of targeted therapies that specifically address molecular alterations associated with kidney cancer. Targeted therapies, including tyrosine kinase inhibitors (TKIs) & mammalian target of rapamycin (mTOR) inhibitors, have demonstrated efficacy in inhibiting cancer cell growth and prolonging progression-free survival in individuals diagnosed with advanced renal cell carcinoma. Moreover, immunotherapy has revolutionized the treatment landscape for kidney cancer, particularly checkpoint inhibitors that unleash the immune system to attack cancer cells. Drugs targeting programmed cell death protein 1 (PD-1) & cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown promising results in clinical trials, offering new therapeutic alternatives for patients who do not respond to conventional treatments. Furthermore, collaborative efforts between pharmaceutical companies & research institutions drive innovation in developing kidney cancer drugs. Partnerships focus on identifying novel biomarkers, exploring combination therapies, and conducting clinical trials to expand treatment options and improve patient outcomes. However, access to innovative kidney cancer drugs can be limited by regulatory hurdles, reimbursement policies, and affordability issues, which may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Kidney Cancer Drugs. The growth and trends of Kidney Cancer Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Kidney Cancer Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Cancer Type

• Renal Cell Carcinoma (RCC)
• Transitional Cell Cancer
• Wilms Tumor
• Renal Sarcoma

By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies

By Drug Class

• Angiogenesis Inhibitors
• Monoclonal Antibodies
• Mtor Inhibitors
• Cytokine Immunotherapy (IL-2)
• Other Drug Classes

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Distribution Channel

• Hospital Pharmacy
• Brick and Mortar
• E-Commerce

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Kidney Cancer Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Kidney Cancer Drugs market include Active Biotech AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co. Ltd., Exelixis Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GSK Plc, Helsinn Healthcare SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. KIDNEY CANCER DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Cancer Type
  • 3.7.2 Market Attractiveness Analysis By Therapy
  • 3.7.3 Market Attractiveness Analysis By Drug Class
  • 3.7.4 Market Attractiveness Analysis By Route of Administration
  • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY CANCER TYPE

• 5.1. Overview By Cancer Type
• 5.2. Historical and Forecast Data Analysis By Cancer Type
• 5.3. Renal Cell Carcinoma (RCC) Historic and Forecast Sales By Regions
• 5.4. Transitional Cell Cancer Historic and Forecast Sales By Regions
• 5.5. Wilms Tumor Historic and Forecast Sales By Regions
• 5.6. Renal Sarcoma Historic and Forecast Sales By Regions

6. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY THERAPY

• 6.1. Overview By Therapy
• 6.2. Historical and Forecast Data Analysis By Therapy
• 6.3. Targeted Therapy Historic and Forecast Sales By Regions
• 6.4. Immunotherapy Historic and Forecast Sales By Regions
• 6.5. Chemotherapy Historic and Forecast Sales By Regions
• 6.6. Other Therapies Historic and Forecast Sales By Regions

7. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DRUG CLASS

• 7.1. Overview By Drug Class
• 7.2. Historical and Forecast Data Analysis By Drug Class
• 7.3. Angiogenesis Inhibitors Historic and Forecast Sales By Regions
• 7.4. Monoclonal Antibodies Historic and Forecast Sales By Regions
• 7.5. Mtor Inhibitors Historic and Forecast Sales By Regions
• 7.6. Cytokine Immunotherapy (IL-2) Historic and Forecast Sales By Regions
• 7.7. Other Drug Classes Historic and Forecast Sales By Regions

8. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 8.1. Overview By Route of Administration
• 8.2. Historical and Forecast Data Analysis By Route of Administration
• 8.3. Oral Historic and Forecast Sales By Regions
• 8.4. Intravenous Historic and Forecast Sales By Regions
• 8.5. Subcutaneous Historic and Forecast Sales By Regions

9. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 9.1. Overview By Distribution Channel
• 9.2. Historical and Forecast Data Analysis By Distribution Channel
• 9.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 9.4. Brick and Mortar Historic and Forecast Sales By Regions
• 9.5. E-Commerce Historic and Forecast Sales By Regions

10. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE KIDNEY CANCER DRUGS COMPANIES

• 11.1. Kidney Cancer Drugs Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF KIDNEY CANCER DRUGS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Active Biotech AB
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Amgen Inc.
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Astellas Pharma Inc.
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. AstraZeneca PLC
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Bayer AG
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Bristol-Myers Squibb Company
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Eisai Co. Ltd.
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. Exelixis Inc.
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. F. Hoffmann-La Roche Ltd.
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Genentech Inc.
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments
• 12.13. GSK Plc
  • 12.13.1 Company Overview
  • 12.13.2 Company Revenue
  • 12.13.3 Products
  • 12.13.4 Recent Developments
• 12.14. Helsinn Healthcare SA
  • 12.14.1 Company Overview
  • 12.14.2 Company Revenue
  • 12.14.3 Products
  • 12.14.4 Recent Developments
• 12.15. Johnson & Johnson Services Inc.
  • 12.15.1 Company Overview
  • 12.15.2 Company Revenue
  • 12.15.3 Products
  • 12.15.4 Recent Developments
• 12.16. Merck & Co. Inc.
  • 12.16.1 Company Overview
  • 12.16.2 Company Revenue
  • 12.16.3 Products
  • 12.16.4 Recent Developments
• 12.17. Novartis AG
  • 12.17.1 Company Overview
  • 12.17.2 Company Revenue
  • 12.17.3 Products
  • 12.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies